130 related articles for article (PubMed ID: 19056723)
1. Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments.
Schüklenk U; Lowry C
Br Med Bull; 2009; 89():7-22. PubMed ID: 19056723
[TBL] [Abstract][Full Text] [Related]
2. Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society.
Chahal M
J Med Ethics; 2010 Jun; 36(6):367-70. PubMed ID: 20511354
[TBL] [Abstract][Full Text] [Related]
3. Access for the terminally ill to experimental medical innovations: a three-pronged threat.
Bender S; Flicker L; Rhodes R
Am J Bioeth; 2007 Oct; 7(10):3-6. PubMed ID: 17926208
[No Abstract] [Full Text] [Related]
4. Conflicts of interest in research involving human beings.
Greco D; Diniz NM
J Int Bioethique; 2008; 19(1-2):143-54, 202-3. PubMed ID: 18664007
[TBL] [Abstract][Full Text] [Related]
5. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
6. Freebies for subject 641: a discussion of the ethical prospect of providing drug trial subjects with post-trial access to the drug tested--a Canadian perspective.
Hutt LE
Health Law J; 1998; 6 Spec No():169-87. PubMed ID: 14746066
[TBL] [Abstract][Full Text] [Related]
7. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
8. Nurses' attitudes towards artificial food or fluid administration in patients with dementia and in terminally ill patients: a review of the literature.
Bryon E; de Casterlé BD; Gastmans C
J Med Ethics; 2008 Jun; 34(6):431-6. PubMed ID: 18511614
[TBL] [Abstract][Full Text] [Related]
9. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
10. FDA's compassion for desperate drug companies.
Annas GJ
Hastings Cent Rep; 1990; 20(1):35-7. PubMed ID: 2179165
[TBL] [Abstract][Full Text] [Related]
11. Towards the development of ethical practices in paediatric clinical trials: the special position of the terminally ill child.
Keough WJ
J Law Med; 2006 Feb; 13(3):370-86. PubMed ID: 16506728
[TBL] [Abstract][Full Text] [Related]
12. Should post-trial provision of beneficial experimental interventions be mandatory in developing countries?
Zong Z
J Med Ethics; 2008 Mar; 34(3):188-92. PubMed ID: 18316461
[TBL] [Abstract][Full Text] [Related]
13. Access to life-saving medicines and intellectual property rights: an ethical assessment.
Schroeder D; Singer P
Camb Q Healthc Ethics; 2011 Apr; 20(2):279-89. PubMed ID: 21435303
[No Abstract] [Full Text] [Related]
14. Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines.
Pinxten W; Nys H; Dierickx K
J Med Ethics; 2010 Dec; 36(12):791-4. PubMed ID: 20852303
[TBL] [Abstract][Full Text] [Related]
15. Finding boundaries inside prison walls: case study of a terminally ill inmate.
O'Connor MF
Death Stud; 2004 Jan; 28(1):63-76. PubMed ID: 14969279
[TBL] [Abstract][Full Text] [Related]
16. [Terminal sedation in mentally competent patients: no overriding medical-ethical arguments against in the medical literature].
van Deijck RH; Rondas AA; Berghmans RL
Ned Tijdschr Geneeskd; 2003 Dec; 147(50):2479-83. PubMed ID: 14708215
[TBL] [Abstract][Full Text] [Related]
17. An analysis of common ethical justifications for compassionate use programs for experimental drugs.
Raus K
BMC Med Ethics; 2016 Oct; 17(1):60. PubMed ID: 27756370
[TBL] [Abstract][Full Text] [Related]
18. Access before approval--a right to take experimental drugs?
Okie S
N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
[No Abstract] [Full Text] [Related]
19. Committees for Ethics in Research involving human subjects.
Hossne WS; Vieira S; De Freitas CB
J Int Bioethique; 2008; 19(1-2):131-41, 200. PubMed ID: 18664006
[TBL] [Abstract][Full Text] [Related]
20. Emerging science, emerging ethical issues: who should fund innate alloimmunity-suppressing drugs?
Land WG; Gutmann T; Daar AS
Acta Chir Belg; 2008; 108(1):73-82. PubMed ID: 18411578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
